CIK 0001070494 · Large accelerated filer
ACADIA PHARMACEUTICALS INC
Sign in to watch- Ticker
- ACAD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 061376651
- Phone
- 858-558-2871
- Business address
- 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $69,342
- in 1 filing
Net −$69,342. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale | −3,321 | $20.88 | $69K | 71,322 |
| 2026-10-15 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Grant or award | +6,815 | 74,643 | ||
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +14,292 | $17.84 | $255K | 82,120 |
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −5,000 | $29.00 | $145K | 77,120 |
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −9,292 | $29.34 | $273K | 67,828 |
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,292 | 60,423 | ||
| 2026-08-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +5,849 | $17.84 | $104K | 73,677 |
| 2026-08-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −5,849 | $29.00 | $170K | 67,828 |
| 2026-08-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,849 | 74,715 | ||
| 2026-07-30 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Sale | −16,508 | $26.13 | $431K | 19,044 |
| 2026-07-30 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Sale | −50 | $26.17 | $1K | 18,994 |
| 2026-07-29 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Option exercise | +32,272 | 35,552 | ||
| 2026-07-29 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Option exercise · Restricted Stock Units | −32,272 | 32,272 | ||
| 2026-06-26 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Sale 10b5-1 | −11,421 | $26.08 | $298K | 13,088 |
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Grant or award | +18,622 | 3,677,357 | ||
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Grant or award | +18,622 | 39,384,587 | ||
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +32,008 | 32,008 | ||
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +32,008 | 32,008 | ||
| 2026-05-29 | Ndu Adora Director | Option exercise | +8,107 | 32,908 | ||
| 2026-05-29 | Ndu Adora Director | Option exercise · Restricted Stock Units | −8,107 | 0 |
Page 1 of 49 · 979 trades